To analyze the auxiliary application effect of Xiao’er Tuihuang Jianpi free-fried granule combined with bifidobacterium triple viable powder for treating neonatal jaundice. Methods: 96 neonates with jaundice who has born in the hospital were selected and were divided into two groups (48 cases in each group) according to simple random sampling method from December 2022 to December 2023. The neonates in the control group were given bifidobacterium triple viable powder and the neonates in the study group were given Xiao’ er Tuihuang Jianpi free-fried granule combined with bifidobacterium triple viable powder. The efficacy, the levels of the T lymphocyte subsets indexes before and after treatment and the rate of adverse reactions of the neonates were compared between groups. Results: The total effective rate (95.8%) of the neonates in the study group after treatment was significantly higher than that (81.3%) of the neonates in the control group. The time of hospital stay (5.65±0.70 d) of the neonates in the study group after treatment was significantly less than that (7.01±0.86 d) of the neonates in the control group. The decreased degree of the bilirubin level (8.96±1.12 mg/dl) of the neonates in the study group after treatment was significantly higher than that (7.04±0.97mg/dl) of the neonates in the control group. The levels of CD3+, CD4+, CD4+/CD8+ of the neonates in the study group after treatment were significantly higher than those of the neonates in the control group (all P<0.05). There was no significant difference in the CD8+ level of the neonates before and after treatment between the two groups. There was no significant difference in the total incidence of the adverse reactions (6.2% vs. 18.8%) of the neonates between the two groups (P＞0.05). Conclusion: The application of Xiao’er Tuihuang  Jianpi free-fried granule combined with bifidobacterium triple viable powder for auxiliary treating the neonatal jaundice has better effect, and which has good regulatory effect on the levels of the T lymphocyte subsets of these neonates, and without increasing the adverse reactions incidence.